Search results
Showing results for
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
©
John Cairns
Sixty Seconds with Fadi Issa
Professor Fadi Issa is Professor of Transplantation in NDS, and recently took up the divisional role of Academic Lead for Research Funding. In this interview, Fadi reflects on the importance of resilience and clarity of thinking, shares what the role involves, what is changing in the funding landscape, and offers practical advice for early career researchers navigating competition, rejection and the realities of grant writing.